With the advent of personalized med...

With the advent of personalized medicine and purported "race-based therapies" of the like kind as Bil-Dil in the freshs it is time the pharmaceutical industry makes a more agreemented effort to engage racial and ethnic minority collections and the rural poor in clinical research.

For a certain quantity of time, the industry has recognized the ne to do a better do job-work engaging disparate communities in clinical research. There have been a certain steps forward in this area, as it was as the FDAMA Act of 1997 However, they have fallen short: minority cluster representation in clinical trials remains substantially